跳转至内容
Merck
CN

C-059

氯氮平标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C18H19ClN4
化学文摘社编号:
5786-21-0
分子量:
326.82
UNSPSC Code:
41116107
MDL number:
MFCD00153785
NACRES:
NA.24
EC Number:
200-659-6

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

氯氮平标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

InChI key

QZUDBNBUXVUHMW-UHFFFAOYSA-N

InChI

1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3

SMILES string

CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24

grade

certified reference material

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

300

Gene Information

human ... DRD2(1813), HTR2A(3356)

相关类别

General description

经认证的Snap-N-Spike®溶液，用于通过LC/MS或GC/MS进行的临床毒理学，法医分析或尿液药物测试应用。氯氮平在美国以Clozaril®和FazaClo®出售，是一种非典型的抗精神病药物，用于精神分裂症的治疗。

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Clozaril is a registered trademark of Sandoz, Inc.
FazaClo is a registered trademark of Jazz Pharmaceuticals International III Limited
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chun-Hsin Chen et al.
The Journal of clinical psychiatry, 74(5), e424-e430 (2013-06-14)
Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia. Whether or not the beneficial effects can be sustained after discontinuation of metformin needs to be evaluated. We conducted a 24-week randomized
Galvin Vredenburg et al.
Toxicology letters, 222(3), 247-256 (2013-08-07)
Clozapine, an often-prescribed antipsychotic drug, is implicated in severe adverse drug reactions (ADRs). Formation of reactive intermediates by cytochrome P450s (CYPs) has been proposed as a possible explanation for these ADRs. Moreover, a protective role for human glutathione S-transferases (hGSTs)
Shalini Jain et al.
The Journal of clinical investigation, 123(4), 1750-1762 (2013-03-13)
Type 2 diabetes (T2D) has emerged as a major threat to human health in most parts of the world. Therapeutic strategies aimed at improving pancreatic β cell function are predicted to prove beneficial for the treatment of T2D. In the
Chao-Cheng Lin et al.
Journal of clinical psychopharmacology, 33(2), 211-214 (2013-02-21)
Clozapine is the most effective antipsychotic for patients with treatment-refractory schizophrenia, but many adverse effects are noted. Clinicians usually hesitate to switch from clozapine to other antipsychotics because of the risk of a re-emergence or worsening of the psychosis, although
Bianca A Silva et al.
Nature neuroscience, 16(12), 1731-1733 (2013-11-12)
The neural circuits mediating fear to naturalistic threats are poorly understood. We found that functionally independent populations of neurons in the ventromedial hypothalamus (VMH), a region that has been implicated in feeding, sex and aggression, are essential for predator and
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持